Details
Stereochemistry | ACHIRAL |
Molecular Formula | C9H12O3 |
Molecular Weight | 168.1898 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC(OC)=CC(OC)=C1
InChI
InChIKey=LKUDPHPHKOZXCD-UHFFFAOYSA-N
InChI=1S/C9H12O3/c1-10-7-4-8(11-2)6-9(5-7)12-3/h4-6H,1-3H3
DescriptionSources: http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-11/spasfon_ct_9243.pdfCurator's Comment: Description was created using several sources including:
http://www.ema.europa.eu/docs/en_GB/document_library/contacts/ochassany_DI.pdf; https://www.ncbi.nlm.nih.gov/pubmed/14017697; https://www.ncbi.nlm.nih.gov/pubmed/15122041; https://www.ncbi.nlm.nih.gov/pubmed/17439513
Sources: http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-11/spasfon_ct_9243.pdf
Curator's Comment: Description was created using several sources including:
http://www.ema.europa.eu/docs/en_GB/document_library/contacts/ochassany_DI.pdf; https://www.ncbi.nlm.nih.gov/pubmed/14017697; https://www.ncbi.nlm.nih.gov/pubmed/15122041; https://www.ncbi.nlm.nih.gov/pubmed/17439513
1,3,5-trimethoxybenzene (trade name Spasfon (R), registered and marketed in France) is an antispasmodic drug acting on smooth muscle. It is indicated for symptomatic treatment of pain related to functional disorders of the gastrointestinal tract and biliary tract, urinary tract (renal colic) or gynecological pain, and to reduce early contractions during a pregnancy. It is widely prescribed in cases of intestinal disorders including infectious and other bowel disease, gastrointestinal symptoms, urinary tract and genital tract disease. Spasfon is produced as film-coated tablets and solution for injection. 1,3,5-Trimethoxybenzene is a key component of the Chinese rose odor. This compound is synthesized in three successive methylation steps from phloroglucinol, the initial precursor.
Originator
Sources: http://www.shp-asso.org/index.php?PAGE=lafon
Curator's Comment: In 2002, the Laboratory Louis Lafon was taken by Cephalon (USA) that acquired the entire portfolio of Lafon products sold in France including SPASFON(R) (phloroglucinol).
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Secondary | SPASFON(R) Approved UseIndicated for symptomatic treatment of pain related to functional disorders of the gastrointestinal tract
and biliary tract; treatment of spasm and acute pain of the urinary tract: renal colic; symptomatic treatment of painful spasm in gynaecology; adjuvant therapy for contractions during pregnancy, in combination with rest Launch Date1973 |
|||
Palliative | SPASFON(R) Approved UseIndicated for symptomatic treatment of pain related to functional disorders of the gastrointestinal tract
and biliary tract; treatment of spasm and acute pain of the urinary tract: renal colic; symptomatic treatment of painful spasm in gynaecology; adjuvant therapy for contractions during pregnancy, in combination with rest Launch Date1973 |
|||
Palliative | SPASFON(R) Approved UseIndicated for symptomatic treatment of pain related to functional disorders of the gastrointestinal tract
and biliary tract; treatment of spasm and acute pain of the urinary tract: renal colic; symptomatic treatment of painful spasm in gynaecology; adjuvant therapy for contractions during pregnancy, in combination with rest Launch Date1973 |
PubMed
Title | Date | PubMed |
---|---|---|
Metallocyclic receptors with Re(I)/Os(II)-based moieties: molecular photophysics and selective molecular sensing. | 2001 Jun 1 |
|
Reactions of N-methyl-N-(4-biphenylyl)nitrenium ion with electron-rich arenes: laser flash photolysis and product studies. | 2002 Apr 10 |
|
Biosynthesis of the major scent components 3,5-dimethoxytoluene and 1,3,5-trimethoxybenzene by novel rose O-methyltransferases. | 2002 Jul 17 |
|
Computational insight into the reaction intermediates in the glycosylation reaction assisted by donor heteroatoms. | 2003 Feb 7 |
|
Control of extremely fast competitive consecutive reactions using micromixing. Selective Friedel-Crafts aminoalkylation. | 2005 Aug 24 |
|
Adsorption of single-ring organic compounds to wood charcoals prepared under different thermochemical conditions. | 2005 Jun 1 |
|
Electron capture in charge-tagged peptides. Evidence for the role of excited electronic states. | 2007 Dec |
|
Solvent-free iodination of organic molecules using the I(2)/urea-H(2)O(2) reagent system. | 2007 Feb 21 |
|
Bimolecular hole transfer from the trimethoxybenzene radical cation in the excited state. | 2007 Jun 7 |
|
Transcriptomic and metabolite analyses of Cabernet Sauvignon grape berry development. | 2007 Nov 22 |
|
Investigation of the dynamic stereochemistry of dimesityl-2,4,6-trimethoxyphenylmethane by complete lineshape analysis and 2D EXSY NMR spectroscopy. | 2008 Apr |
|
Validation of a quantitative NMR method for suspected counterfeit products exemplified on determination of benzethonium chloride in grapefruit seed extracts. | 2008 Aug 5 |
|
Sila-haloperidol, a silicon analogue of the dopamine (D2) receptor antagonist haloperidol: synthesis, pharmacological properties, and metabolic fate. | 2008 Jan |
|
A carbene-carbene complex equilibrium. | 2010 Aug 11 |
|
Mesit-yl(2,4,6-trimeth-oxy-phen-yl)borinic acid. | 2010 Jun 18 |
|
(E)-1-(2-Fur-yl)-3-(2,4,6-trimeth-oxy-phen-yl)prop-2-en-1-one. | 2010 Sep 15 |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2538427
Assays for halogenation by neutrophils and eosinophils from
the blood of normal volunteers and patients with eosinophilia were carried out using labeled with radioactive carbon 1,3,5-trimethoxybenzene at 1 X 10(-4) M (14C = 0.5 nCi/ml). Total amount of active halogen trapped by 1,3,5-trimethoxybenzene from eosinophils increases by over 2-fold as the added bromide concentration increases from 0 to 100 microM, with approximately 40 nmol of halogen trapped per million cells at the highest bromide level.
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000092189
Created by
admin on Fri Dec 15 18:07:33 GMT 2023 , Edited by admin on Fri Dec 15 18:07:33 GMT 2023
|
PRIMARY | |||
|
210-673-4
Created by
admin on Fri Dec 15 18:07:33 GMT 2023 , Edited by admin on Fri Dec 15 18:07:33 GMT 2023
|
PRIMARY | |||
|
69301
Created by
admin on Fri Dec 15 18:07:33 GMT 2023 , Edited by admin on Fri Dec 15 18:07:33 GMT 2023
|
PRIMARY | |||
|
90060
Created by
admin on Fri Dec 15 18:07:33 GMT 2023 , Edited by admin on Fri Dec 15 18:07:33 GMT 2023
|
PRIMARY | |||
|
SUB15620MIG
Created by
admin on Fri Dec 15 18:07:33 GMT 2023 , Edited by admin on Fri Dec 15 18:07:33 GMT 2023
|
PRIMARY | |||
|
38716
Created by
admin on Fri Dec 15 18:07:33 GMT 2023 , Edited by admin on Fri Dec 15 18:07:33 GMT 2023
|
PRIMARY | RxNorm | ||
|
621-23-8
Created by
admin on Fri Dec 15 18:07:33 GMT 2023 , Edited by admin on Fri Dec 15 18:07:33 GMT 2023
|
PRIMARY | |||
|
00VJI3VG3D
Created by
admin on Fri Dec 15 18:07:33 GMT 2023 , Edited by admin on Fri Dec 15 18:07:33 GMT 2023
|
PRIMARY | |||
|
SUB49266
Created by
admin on Fri Dec 15 18:07:33 GMT 2023 , Edited by admin on Fri Dec 15 18:07:33 GMT 2023
|
PRIMARY | |||
|
31038
Created by
admin on Fri Dec 15 18:07:33 GMT 2023 , Edited by admin on Fri Dec 15 18:07:33 GMT 2023
|
PRIMARY | |||
|
C015560
Created by
admin on Fri Dec 15 18:07:33 GMT 2023 , Edited by admin on Fri Dec 15 18:07:33 GMT 2023
|
PRIMARY | |||
|
DTXSID0045963
Created by
admin on Fri Dec 15 18:07:33 GMT 2023 , Edited by admin on Fri Dec 15 18:07:33 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD